Testing a new medicine for healthy adults
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must be a healthy non-smoker.
- Your body mass index (BMI) must be between 18.0 and 32.0, and you must weigh at least 50 kg.
- You cannot have any significant medical conditions or take most prescription or over-the-counter medicines.
- You must not have participated in another clinical trial recently or have been exposed to GV-100 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for healthy volunteers to see how a new experimental drug (JMKX003142) interacts with other drugs in the body. It helps find the right dose for future patients.
This trial tests how a new drug (JMKX003142) interacts with other substances in healthy volunteers. It helps researchers understand how the drug is absorbed and processed, which is a key step before it can be tested in patients.
This study tests a new medicine (JMKX003142) in healthy adults to see if it affects the heart's rhythm. If you qualify, you may help determine whether the drug is safe to use in future patients.
This study looks at how a new drug (JMKX003142) is absorbed and broken down in the body. It involves healthy men and will help determine safe dosing for future studies.
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
This is an early-stage study testing a new investigational drug called IG001119 in people who are in good health. Researchers will give increasing doses to small groups to learn how the drug is processed by the body and to check for any side effects.
Hear when a new ADPKD (Autosomal Dominant Polycystic Kidney Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.